Project Grant HT94252410649
Award Date
6/15/24
Completion Date
6/14/27
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This $698,456.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports the "Development of a Universal mRNA Vaccine Targeting APC Mutations for Colorectal Cancer Prevention" at the Sloan-Kettering Institute for Cancer Research in New York, NY. The three-year award, running from November 1, 2024 to October 31, 2027, will fund innovative research to develop a novel mRNA-based vaccine targeting...
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
The federal Project Grant award of $436,398.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by Eligo Bioscience in France to engineer oncobacteria to remodel the colorectal cancer microenvironment. The award period runs from September 1, 2025 to August 31, 2027. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical solutions to critical...
This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...
This federal Project Grant award of $1,622,612.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports preclinical validation of novel combination therapeutic strategies targeting KRAS and BRAF mutated colorectal cancer. The award was granted to The University of Texas M.D. Anderson Cancer Center to conduct this advanced biomedical research, with the goal of enabling near-term clinical examination of the developed therapies. The 3-year project...
The Department of Defense's Defense Health Agency has awarded a $1,344,002 Project Grant to Cold Spring Harbor Laboratory (CSHL) under the Military Medical Research and Development program (CFDA 12.420). This four-year grant, running from August 1, 2024 to July 31, 2028, will fund research to enhance immunity in colorectal cancer liver metastases. CSHL, a renowned non-profit research institution, will leverage its expertise in cancer biology, genomics, and molecular biology to advance this...
This Project Grant award, valued at $543,285.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, the University of Washington will conduct research to develop new FDA-approved combination therapies for transforming the treatment of rhabdomyosarcoma, a rare...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $6,965,603.00 to the University of Washington to develop a multiantigen vaccine (STEMVAC) for adjuvant treatment of patients with moderate or extensive residual triple-negative breast cancer. The award period runs from June 15, 2025 to June 14, 2029. As a major research institution, the University of Washington will leverage its extensive research...
This $835,531 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will fund a research project at The Johns Hopkins University to develop a pooled mutant KRAS-targeted long peptide vaccine combined with anti-PD-1 and anti-CTLA-4 antibodies for patients with stage IV mismatch repair-proficient (MMR-P) pancreatic ductal adenocarcinoma. The project aims to transform healthcare for military service members and the broader...
The federal Project Grant award of $1,224,997.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Cold Spring Harbor Laboratory (CSHL) to conduct research aimed at "ENHANCING IMMUNITY IN COLORECTAL CANCER LIVER METASTASES." This grant, with a performance period from August 1, 2024 to July 31, 2028, will allow CSHL, a renowned non-profit research institution, to leverage its expertise in cancer biology, genomics,...